CG0070

BIOLOGICAL4 trials

Conditions

Bladder CancerMuscle-Invasive Bladder CarcinomaNon Muscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer

Phase 1

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

CompletedNCT04610671

H. Lee Moffitt Cancer Center and Research InstituteBladder Cancer, Muscle-Invasive Bladder Carcinoma

Start: 2020-10-26End: 2024-07-25Updated: 2026-02-27

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

Active, not recruitingNCT06253845

H. Lee Moffitt Cancer Center and Research InstituteNon-muscle Invasive Bladder Cancer

Start: 2024-03-01End: 2027-09-01Updated: 2026-07-02

Phase 2

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

CompletedNCT02365818

CG Oncology, Inc.Bladder Cancer

Start: 2015-06-02End: 2019-02-28Updated: 2021-04-14

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

CompletedNCT04387461

CG Oncology, Inc.Non Muscle Invasive Bladder Cancer

Start: 2020-12-08End: 2024-05-28Updated: 2024-09-25

2025-11-12

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.

2024-11-0916 citations

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

2024-06-0634 citations

Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

Journal of Clinical Oncology2024-06-0110 citations

Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).

Journal of Clinical Oncology2023-06-011 citations

666 Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)

Regular and Young Investigator Award Abstracts2022-11-013 citations

Abstract CT529: A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer

Cancer Research2022-06-151 citations

CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Journal of Clinical Oncology2022-06-0131 citations

Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).

Journal of Clinical Oncology2022-06-013 citations

955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)

2021-11-018 citations

MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL

The Journal of Urology2019-04-0113 citations

LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL

The Journal of Urology2018-04-014 citations

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

2017-07-26175 citations

CG0070

Sponsors

Conditions

Phase 1

Phase 2

Related Papers